Switch theme
Sign up to access all valuation multiples
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.
1997
748
LTM Revenue $104M
LTM EBITDA n/a
$326M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scinopharm Taiwan has a last 12-month revenue of $104M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Scinopharm Taiwan achieved revenue of $103M and an EBITDA of $27.5M.
Scinopharm Taiwan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scinopharm Taiwan valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $96.2M | $103M | XXX | XXX | XXX |
| Gross Profit | $37.8M | $36.7M | XXX | XXX | XXX |
| Gross Margin | 39% | 36% | XXX | XXX | XXX |
| EBITDA | $24.7M | $27.5M | XXX | XXX | XXX |
| EBITDA Margin | 26% | 27% | XXX | XXX | XXX |
| Net Profit | $10.7M | $8.7M | XXX | XXX | XXX |
| Net Margin | 11% | 8% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Scinopharm Taiwan's stock price is TWD 18 (or $1).
Scinopharm Taiwan has current market cap of TWD 14.3B (or $431M), and EV of TWD 10.8B (or $326M).
See Scinopharm Taiwan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $326M | $431M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Scinopharm Taiwan has market cap of $431M and EV of $326M.
Scinopharm Taiwan's trades at 3.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Scinopharm Taiwan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Scinopharm Taiwan and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $326M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.9x | XXX | XXX | XXX |
| P/E | 42.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 23.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpScinopharm Taiwan's NTM/LTM revenue growth is 3%
Scinopharm Taiwan's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $39K for the same period.
Over next 12 months, Scinopharm Taiwan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Scinopharm Taiwan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Scinopharm Taiwan and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $39K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scinopharm Taiwan acquired XXX companies to date.
Last acquisition by Scinopharm Taiwan was XXXXXXXX, XXXXX XXXXX XXXXXX . Scinopharm Taiwan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Scinopharm Taiwan founded? | Scinopharm Taiwan was founded in 1997. |
| Where is Scinopharm Taiwan headquartered? | Scinopharm Taiwan is headquartered in Taiwan. |
| How many employees does Scinopharm Taiwan have? | As of today, Scinopharm Taiwan has 748 employees. |
| Is Scinopharm Taiwan publicy listed? | Yes, Scinopharm Taiwan is a public company listed on TAI. |
| What is the stock symbol of Scinopharm Taiwan? | Scinopharm Taiwan trades under 1789 ticker. |
| When did Scinopharm Taiwan go public? | Scinopharm Taiwan went public in 2011. |
| Who are competitors of Scinopharm Taiwan? | Similar companies to Scinopharm Taiwan include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scinopharm Taiwan? | Scinopharm Taiwan's current market cap is $431M |
| What is the current revenue of Scinopharm Taiwan? | Scinopharm Taiwan's last 12-month revenue is $104M. |
| What is the current EV/Revenue multiple of Scinopharm Taiwan? | Current revenue multiple of Scinopharm Taiwan is 3.1x. |
| What is the current revenue growth of Scinopharm Taiwan? | Scinopharm Taiwan revenue growth between 2023 and 2024 was 7%. |
| Is Scinopharm Taiwan profitable? | Yes, Scinopharm Taiwan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
